Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis.
about
Potentiating effects of MPL on DSPC bearing cationic liposomes promote recombinant GP63 vaccine efficacy: high immunogenicity and protectionTargeting Leishmania major Antigens to Dendritic Cells In Vivo Induces Protective ImmunityVector transmission of leishmania abrogates vaccine-induced protective immunityLeishmania donovani: immunostimulatory cellular responses of membrane and soluble protein fractions of splenic amastigotes in cured patient and hamstersVaccines to combat the neglected tropical diseases.Testing of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis, the main causative agent of cutaneous leishmaniasis in the New World.Identifying vaccine targets for anti-leishmanial vaccine developmentNucleosomal histone proteins of L. donovani: a combination of recombinant H2A, H2B, H3 and H4 proteins were highly immunogenic and offered optimum prophylactic efficacy against Leishmania challenge in hamsters.Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SE.Th1 Platform Immune Responses Against Leishmania major Induced by Thiol-Specific Antioxidant-Based DNA VaccinesKSAC, a defined Leishmania antigen, plus adjuvant protects against the virulence of L. major transmitted by its natural vector Phlebotomus duboscqiTh1 stimulatory proteins of Leishmania donovani: comparative cellular and protective responses of rTriose phosphate isomerase, rProtein disulfide isomerase and rElongation factor-2 in combination with rHSP70 against visceral leishmaniasis.Applying TLR synergy in immunotherapy: implications in cutaneous leishmaniasis.KSAC, the first defined polyprotein vaccine candidate for visceral leishmaniasisIn silico analysis of six known Leishmania major antigens and in vitro evaluation of specific epitopes eliciting HLA-A2 restricted CD8 T cell response.Evaluation of DNA encoding acidic ribosomal protein P2 of Cryptosporidium parvum as a potential vaccine candidate for cryptosporidiosis.From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE.CD8(+) T cells in leishmania infections: friends or foes?Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cellsAdjuvants for Leishmania vaccines: from models to clinical application.Consultation meeting on the development of therapeutic vaccines for post kala azar dermal leishmaniasisDifferential Immune Response against Recombinant Leishmania donovani Peroxidoxin 1 and Peroxidoxin 2 Proteins in BALB/c Mice.Identification of Leishmania infantum chagasi proteins in urine of patients with visceral leishmaniasis: a promising antigen discovery approach of vaccine candidates.Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvantVaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against leishmania major infectionDNA immunization with the gene encoding P4 nuclease of Leishmania amazonensis protects mice against cutaneous LeishmaniasisThe Leishmania infantum acidic ribosomal protein P0 administered as a DNA vaccine confers protective immunity to Leishmania major infection in BALB/c mice.Interleukin-6 has differential influence on the ability of adjuvant formulations to potentiate antibody responses to a Plasmodium falciparum blood-stage vaccineKinetoplastids: related protozoan pathogens, different diseases.Coencapsulation of CpG oligodeoxynucleotides with recombinant Leishmania major stress-inducible protein 1 in liposome enhances immune response and protection against leishmaniasis in immunized BALB/c miceEvaluation of recombinant Leishmania polyprotein plus glucopyranosyl lipid A stable emulsion vaccines against sand fly-transmitted Leishmania major in C57BL/6 miceStrategic evaluation of vaccine candidate antigens for the prevention of Visceral Leishmaniasis.Real-time in vivo green fluorescent protein imaging of a murine leishmaniasis model as a new tool for Leishmania vaccine and drug discovery.Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant.Leishmania infantum sterol 24-c-methyltransferase formulated with MPL-SE induces cross-protection against L. major infection.Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis.Cutaneous leishmaniasis: progress towards a vaccine.Optimized subunit vaccine protects against experimental leishmaniasis.Immunization with Leishmania major exogenous antigens protects susceptible BALB/c mice against challenge infection with L. major.Use of defined TLR ligands as adjuvants within human vaccines.
P2860
Q27305883-A12E82B3-F901-404D-8384-380E6DD0CB7DQ27312070-F9605412-14D9-4895-9C04-A57609B9F62EQ27316727-C93EDADB-7A80-4480-B407-C654B3C0B22CQ28480398-57ACF60B-BD7D-4868-883B-04D7410ECBE4Q30425005-0A0F8B75-43D6-4642-90BF-40208A86206DQ30444062-A2BA290C-E137-40A4-9E19-BDD4266AB6AEQ33693899-AA1675FC-D2C6-4871-B603-E575C60A633FQ33753259-4BACB7B9-9158-47C0-8022-2A116DE40923Q33870336-E69FA7FB-8C20-40BD-B551-1C5E4BB81BE4Q34068700-AA1D3818-5880-40F4-B59D-FB909A09F12BQ34235741-D43A813B-4553-4D4A-ACE1-F9A3E65C3F73Q34277331-7365DF1F-C163-45FA-81E1-D43A522CF1DDQ35029988-A3BB860F-89AF-4373-BF7A-673C9A0524DBQ35138682-04D9719D-4075-436B-B585-03A3C546F966Q35198753-BA4300AD-B156-4B51-875F-F5978CE5B15DQ35532405-36C1D1D2-4C1B-4270-90EF-7E93606DF298Q35809113-3DA36F1C-B658-45E3-A1BA-31105DFD5160Q35927465-9D5A03D1-C7C6-451D-B44D-EBF9DFC7D6C3Q35947234-DDE8C560-7B91-48C5-8AE9-60D2B575A6CBQ36021357-6D398832-FB06-4D47-B428-E31511CB84CFQ36025524-EDBCDDDC-3F98-4163-B2C1-0C1BB99B5479Q36035026-7FBDAAB5-965F-4AF7-9CF1-B4877E77B589Q36105743-68456BF9-6174-41C1-B845-9F3B8246C9A8Q36141819-63A15433-E23B-4241-928D-A7A1D0126DF5Q36369774-8281F49C-87B5-43A1-A656-E3692A966848Q36376098-0E66AC51-EB8B-4BF3-9FE5-F03C25733B44Q36376320-C7BFD5C2-F286-4009-B181-FFE88297C116Q36484748-611D5CD3-E26E-420B-93B8-CED6838D2504Q36513308-042FB36D-8F67-4750-8007-393E2AF5795BQ36539044-542DFD24-CAC8-44CF-8C24-AB6B40D5959AQ36682576-DE1B4B9C-953F-4015-95FE-2FDF1C973AEEQ36958635-12E212A5-FFFA-46DC-80CF-3CB260DA2B57Q36994297-EBABE523-D2AA-4211-992E-F407B05E3739Q37109519-DE70091E-5C36-4523-9A6C-C8310D2CD564Q37223654-852EA51D-14C0-447B-88E5-226EC56AF508Q37225443-4EC8C5AD-AF47-4051-9B31-E74E686B695DQ37290119-0866575A-2953-49C0-B3C8-C3E8138FBB7AQ37439440-8DC2CB2F-1188-445A-B1CE-BD250E125F48Q37523834-EB663EA4-D791-43C0-9D9E-C3F4AD6BD941Q37825528-38F6687D-27C5-4456-8224-B22DAE080899
P2860
Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis.
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Immunization with a polyprotei ...... rotects against leishmaniasis.
@ast
Immunization with a polyprotei ...... rotects against leishmaniasis.
@en
Immunization with a polyprotei ...... rotects against leishmaniasis.
@nl
type
label
Immunization with a polyprotei ...... rotects against leishmaniasis.
@ast
Immunization with a polyprotei ...... rotects against leishmaniasis.
@en
Immunization with a polyprotei ...... rotects against leishmaniasis.
@nl
prefLabel
Immunization with a polyprotei ...... rotects against leishmaniasis.
@ast
Immunization with a polyprotei ...... rotects against leishmaniasis.
@en
Immunization with a polyprotei ...... rotects against leishmaniasis.
@nl
P2093
P2860
P1476
Immunization with a polyprotei ...... rotects against leishmaniasis.
@en
P2093
Antonio Campos-Neto
Charisa D Cornellison
Farrokh Modabber
Karen Bernards
Kay Greeson
Rhea N Coler
Yasir A W Skeiky
P2860
P304
P356
10.1128/IAI.70.8.4215-4225.2002
P407
P577
2002-08-01T00:00:00Z